Date:2/6/2008

ross margin of 61% in the same quarter of the previous year due to a less favorable product mix and yields and backorders of higher margin products. Operating expenses for the first quarter of fiscal year 2008 included $1.6 million in costs associated with the proposed merger. Operating expenses were also impacted by $227,000 resulting from the implementation of procedures relating to compliance with the Sarbanes Oxley Act of 2002. The Company is not expected to incur any additional material costs relating to Sarbanes-Oxley for the remaining quarters of fiscal year 2008. During the quarter, the Company incurred $445,000 in SFAS 123(R) stock option expense. For the three months ended December 31, 2007, the net loss totaled $1.3 million or $.07 basic loss per share and $.07 diluted loss per share. Excluding the $1.6 million in costs associated with the proposed merger, the Company would have reported net income of $343,000, or $0.02 per fully diluted share, compared to net income of $361,000, or $0.02 per fully diluted share, in the comparable quarter a year ago.

Guy L. Mayer, Chief Executive Officer of Tutogen Medical, said, "From an operating perspective, we are pleased with the continued double-digit growth in virtually all product and geographic segments. U.S. revenues grew 30%, led by continuing momentum in Surgical Specialties, with a 73% increase, and by a strong 27% increase in domestic dental product revenues."

"We also achieved outstanding growth internationally, with a 32% increase. We believe that our products have the potential to become market leaders internationally, and particularly in Europe. Going forward, as our distribution partners more fully embed our products in international markets, we believe strong and consistent future growth can be achieved."

Mr. Mayer commented on the proposed merger with Regeneration Technologies, Inc. "As the date approaches we very much look forward to the combination of the companies and the signi
'/>"/>

SOURCE Tutogen Medical, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007